AstraZeneca and Avillion unsurprisingly pulled a win on Wednesday for Airsupra in adults, months after an FDA advisory committee voted overwhelmingly in support of the new asthma rescue treatment.
However, the partners weren’t able to secure a nod in adolescents and kids.
Airsupra, formerly known as PT027, is an inhaler combining the two existing compounds albuterol, a short-acting beta2-agonist (SABA), and budesonide, an inhaled corticosteroid (ICS). While asthma patients previously had options that contained either a SABA or an ICS, there were none that combined both components for a bronchodilatory and anti-inflammatory effect.
Bradley Chipps “Current albuterol rescue inhalers alleviate acute symptoms, but do not treat the underlying inflammation in asthma,” Bradley Chipps, former president of the American College of Allergy, Asthma & Immunology and medical director of Capital Allergy & Respiratory Disease Center in Sacramento, said in a news release. “The approval of Airsupra…
Click here to view original post
